Tipharco Pharmaceutical Joint Stock Company (DTG) explains to Shareholders the fluctuations in revenue and profit after tax in the 2024 Financial Statement compared to the same period in 2023 as follows:

In 2024, net revenue will reach VND 364.1 billion, a slight increase of 1.6% compared to 2023 (VND 358.4 billion). However, profit after tax reached VND 23.1 billion, down 25.1% compared to VND 30.9 billion in the previous year.

The main reason for the decline in profit was the increase in cost of goods sold by 2.3%, causing gross profit margin to decrease slightly from VND 78.7 billion to VND 77.9 billion. At the same time, business management costs increased due to the comprehensive upgrade and overhaul process at Tan Duoc factory, causing net profit to decrease to 77.2% compared to the previous year.

In addition, the pharmaceutical market still faces many difficulties, affecting purchasing power and the ability to expand revenue. In response, the company has promoted the diversification of distribution channels, expanded its customer base, and applied a more flexible sales policy to improve its business situation.

In the coming time, the Board of Directors will continue to focus on revenue growth, cost control and optimization of operational efficiency, ready to seize opportunities when the market shows signs of recovery.

For more information, please see the attached file:

1.                  Audited Financial Statements 2024